Earnings summaries and quarterly performance for Transcode Therapeutics.
Executive leadership at Transcode Therapeutics.
Board of directors at Transcode Therapeutics.
Research analysts covering Transcode Therapeutics.
Recent press releases and 8-K filings for RNAZ.
TransCode Therapeutics Announces Publication of Preclinical Data for Glioblastoma Treatment
RNAZ
New Projects/Investments
- TransCode Therapeutics, Inc. announced on January 6, 2026, the publication of preclinical research supporting its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM).
- The study demonstrated that TTX-MC138 was successfully delivered to GBM tumors in murine models following intravenous injection and resulted in extended survival in aggressive glioblastoma models.
- These findings support advancing TTX-MC138 to future clinical evaluation in patients with GBM, leveraging completed investigational new drug (IND) enabling studies and observed safety in Phase 1 clinical trials for non-central nervous system (CNS) cancers.
- TTX-MC138 is currently being evaluated in a Phase 1a clinical trial for metastatic disease, with a Phase 2a clinical trial anticipated to begin in the first half of 2026.
Jan 6, 2026, 1:04 PM
Transcode Therapeutics Amends Preferred Stock Terms
RNAZ
Convertible Preferred Issuance
Delisting/Listing Issues
- Transcode Therapeutics, Inc. filed an Amended and Restated Certificate of Designation for its Series A and Series B Non-Voting Convertible Preferred Stock on October 27, 2025.
- The amendment clarifies that the company shall not issue more than an aggregate of 19.9% of the Common Stock outstanding as of October 8, 2025, pursuant to the Purchase Agreement and Section 6.1.1, prior to stockholder approval of conversion.
- The ability for a preferred stockholder to convert their Preferred Stock into Common Stock in the event of a Nasdaq delisting was removed.
- No additional securities were issued or sold as a result of this filing.
Oct 27, 2025, 1:03 PM
TransCode Therapeutics Completes Phase 1a Clinical Trial for TTX-MC138
RNAZ
New Projects/Investments
Product Launch
- TransCode Therapeutics, Inc. (RNAZ) announced the completion of its Phase 1a clinical trial for TTX-MC138 in metastatic disease, with preliminary data to be presented at the ESMO Congress from October 17-21, 2025.
- The trial achieved its primary safety endpoint, observing no significant treatment-related safety events or dose-limiting toxicities across 16 patients treated with TTX-MC138.
- Preliminary data showed that 44% of patients (7 out of 16) demonstrated apparent stable disease lasting over 4 months, with a median treatment duration of 4 months.
- These results, including the definition of a recommended Phase 2 dose, support the advancement of TTX-MC138 to a Phase 2a clinical trial.
Oct 14, 2025, 12:11 PM
TransCode Therapeutics Completes Phase 1a Clinical Trial for TTX-MC138
RNAZ
New Projects/Investments
- TransCode Therapeutics (NASDAQ: RNAZ) has completed its Phase 1a clinical trial for TTX-MC138, an investigational inhibitor of microRNA-10b.
- The trial successfully met its primary safety endpoint, with no significant treatment-related safety events or dose-limiting toxicities observed in 16 patients.
- A recommended Phase 2 dose was established, and the company plans to advance TTX-MC138 into a Phase 2a clinical trial to evaluate its efficacy in metastatic diseases.
- Preliminary data indicated that 44% of patients (7 out of 16) achieved stable disease lasting 4 months or longer, with a median treatment duration of 4 months.
Oct 14, 2025, 12:06 PM
TransCode Therapeutics Acquires Polynoma and Secures $25 Million Strategic Financing
RNAZ
M&A
New Projects/Investments
CEO Change
- TransCode Therapeutics (RNAZ) announced the acquisition of Polynoma LLC and a concurrent $25 million strategic financing from a subsidiary of CK Life Sciences.
- The $25 million financing, comprising $20 million in cash and a $5 million promissory note, is primarily designated to advance TransCode's lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
- The acquisition expands TransCode's pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma.
- Following these transactions, CK Life Sciences will hold approximately 91% of TransCode on a fully diluted basis, with a combined fully diluted equity value of approximately $165 million.
- Philippe Calais was appointed Chief Executive Officer, Tom Fitzgerald remains Chief Financial Officer, and Elizabeth Czerepak joined the board as an independent member and Chairperson of the Audit Committee.
Oct 8, 2025, 1:57 PM
TransCode Therapeutics (RNAZ) Announces Acquisition of Polynoma and Strategic Financing
RNAZ
M&A
New Projects/Investments
CEO Change
- TransCode Therapeutics (RNAZ) has acquired Polynoma LLC, expanding its pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma.
- Concurrent with the acquisition, TransCode received a $25 million equity investment from CK Life Sciences, which will primarily be used to advance its lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
- The transaction results in CK Life Sciences holding approximately 91% of TransCode on a fully diluted basis, with a combined fully diluted equity value of approximately $165 million.
- Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer and remains Chairman of the Board, while Tom Fitzgerald remains Chief Financial Officer. Elizabeth Czerepak, MBA, was appointed as a new independent Board Member and Chairperson of the Audit Committee.
Oct 8, 2025, 12:01 PM
TransCode Therapeutics Delisting Notice and Appeal Filed
RNAZ
Delisting/Listing Issues
- Nasdaq notice issued: The company’s stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days between March 24, 2025, and May 5, 2025, triggering a delisting notice.
- Reverse split impact: Due to reverse stock splits executed in the prior year and over the previous two-year period with a cumulative ratio of 250:1, the company is not eligible for a compliance period.
- Panel hearing appeal: The company plans to request a hearing before a Nasdaq panel to address the deficiency and remain listed, with the appeal request due no later than May 13, 2025; the report was signed by Interim CEO/CFO Thomas A. Fitzgerald on May 7, 2025.
May 7, 2025, 12:00 AM
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
RNAZ
Delisting/Listing Issues
- The company’s Board approved a 1-for-28 reverse stock split effective at 12:01 a.m. Eastern Time on May 15, 2025
- The reverse split will convert every 28 shares into one share, reducing outstanding shares from 23,341,336 to approximately 833,620 with proportional adjustments to stock options and warrants
- Post-split, common stock will continue trading on the Nasdaq Capital Market under the symbol RNAZ and the CUSIP number will update to 89357L 501 effective upon execution
- The split is part of the company’s initiative to meet Nasdaq’s minimum bid price requirement
May 5, 2025, 9:07 PM
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
RNAZ
Delisting/Listing Issues
- Approval & Purpose: TransCode Therapeutics approved a 1-for-28 reverse stock split on May 2, 2025 to meet Nasdaq's minimum bid price requirement by converting 28 existing shares into 1 new share .
- Share Consolidation: The reverse split will reduce outstanding shares from 23,341,336 to approximately 833,620 .
- Adjustments: Options and warrants are adjusted proportionally , and stockholders will receive rounded-up whole shares when necessary .
May 2, 2025, 8:10 PM
TransCode Therapeutics Advances Phase 1a Trial Progress
RNAZ
New Projects/Investments
- 13 patients have been treated at four escalating doses (0.8 to 4.8 mg/kg) with no significant dose-limiting toxicities reported; two patients maintained stable disease for approximately 7 months.
- Preliminary PK/PD analyses indicate a predictable dose-response relationship and effective miR-10b target engagement at 24 hours post-infusion, supporting advancement to Phase 1b.
May 1, 2025, 1:01 PM
Quarterly earnings call transcripts for Transcode Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more